Elan sees 31% growth in Tysabri sales

Pharmaceutical company Elan has seen a 31% growth in sales of its multiple sclerosis drug Tysabri, and a 24% increase in total revenues of $333.5m for the second quarter of this year.

Net losses for the second quarter were reduced from almost $218m a year earlier to just over $47m.